ZA200903335B - Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors - Google Patents

Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors

Info

Publication number
ZA200903335B
ZA200903335B ZA200903333A ZA200903335A ZA200903335B ZA 200903335 B ZA200903335 B ZA 200903335B ZA 200903333 A ZA200903333 A ZA 200903333A ZA 200903335 A ZA200903335 A ZA 200903335A ZA 200903335 B ZA200903335 B ZA 200903335B
Authority
ZA
South Africa
Prior art keywords
acid derivatives
isonicotinic acid
dhodh inhibitors
amino nicotinic
nicotinic
Prior art date
Application number
ZA200903333A
Other languages
English (en)
Inventor
Palomino Laria Julio Cesar Castro
Sola Montserrat Erra
Toribio Maria Estrella Lozoya
Romero Eloisa Navarro
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200701086A external-priority patent/ES2327372B1/es
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of ZA200903335B publication Critical patent/ZA200903335B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA200903333A 2006-12-22 2009-05-14 Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors ZA200903335B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200603250A ES2319596B1 (es) 2006-12-22 2006-12-22 Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES200701086A ES2327372B1 (es) 2007-04-23 2007-04-23 Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.

Publications (1)

Publication Number Publication Date
ZA200903335B true ZA200903335B (en) 2010-06-30

Family

ID=39319647

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903333A ZA200903335B (en) 2006-12-22 2009-05-14 Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors

Country Status (32)

Country Link
US (2) US8258308B2 (zh)
EP (1) EP2121614B1 (zh)
JP (1) JP5318776B2 (zh)
KR (1) KR101435233B1 (zh)
CN (1) CN101589025B (zh)
AR (1) AR064444A1 (zh)
AU (1) AU2007338321B2 (zh)
BR (1) BRPI0717697B1 (zh)
CA (1) CA2674512C (zh)
CL (1) CL2007003666A1 (zh)
CY (1) CY1113687T1 (zh)
DK (1) DK2121614T3 (zh)
EC (1) ECSP099395A (zh)
ES (2) ES2319596B1 (zh)
HK (1) HK1133014A1 (zh)
HR (1) HRP20120697T1 (zh)
IL (1) IL199188A (zh)
ME (1) ME01475B (zh)
MX (1) MX2009006408A (zh)
MY (1) MY153393A (zh)
NO (1) NO341991B1 (zh)
NZ (1) NZ577017A (zh)
PE (1) PE20081846A1 (zh)
PL (1) PL2121614T3 (zh)
PT (1) PT2121614E (zh)
RS (1) RS52514B (zh)
RU (1) RU2469024C2 (zh)
SI (1) SI2121614T1 (zh)
TW (1) TWI405572B (zh)
UY (1) UY30794A1 (zh)
WO (1) WO2008077639A1 (zh)
ZA (1) ZA200903335B (zh)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2327372B1 (es) * 2007-04-23 2010-08-24 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20120028985A1 (en) * 2008-11-07 2012-02-02 4Sc Ag Combinational therapy for treating autoimmune disease
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2239256A1 (en) * 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
TWI530286B (zh) * 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
EP2360158A1 (en) 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
EP2444088A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP2455081A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
EP2455080A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US10016402B2 (en) 2011-02-08 2018-07-10 Children's Medical Center Corporation Methods for treatment of melanoma
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2594271A1 (en) 2011-11-21 2013-05-22 Almirall, S.A. 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
PT2915804T (pt) 2012-10-31 2019-06-06 Fujifilm Corp Novos derivados de amina ou os seus sais como inibidores do fnt alfa
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
KR20160079123A (ko) 2013-11-22 2016-07-05 젠자임 코포레이션 신경변성 질병을 치료하기 위한 신규한 방법
WO2015154820A1 (en) 2014-04-11 2015-10-15 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds
ES2960598T3 (es) 2014-05-08 2024-03-05 Kiora Pharmaceuticals Gmbh Compuestos para el tratamiento de enfermedades y trastornos oftálmicos
WO2016200778A1 (en) * 2015-06-08 2016-12-15 Children's Medical Center Corporation Methods for treatment of melanoma
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018157843A1 (zh) * 2017-03-02 2018-09-07 中国科学院上海药物研究所 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
TW201834649A (zh) 2017-03-02 2018-10-01 新加坡商亞獅康私人有限公司 癌症療法
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
JP6978251B2 (ja) * 2017-03-03 2021-12-08 アスラン ファーマシューティカルズ ピーティーイー リミテッド がん治療
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2020067412A1 (ja) 2018-09-28 2020-04-02 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
US20220364065A1 (en) 2018-12-21 2022-11-17 National University Corporation Hokkaido University Composition for removing pluripotent stem cells and method of removing pluripotent stem cells
EP3750892A1 (en) 2019-06-14 2020-12-16 Yerevan State University Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
WO2021085582A1 (ja) * 2019-10-31 2021-05-06 富士フイルム株式会社 ピラジン誘導体またはその塩およびその利用
JPWO2022025174A1 (zh) * 2020-07-30 2022-02-03
EP4228640A1 (en) * 2020-10-15 2023-08-23 ASLAN Pharmaceuticals Pte Ltd Treatment of autoimmune diseases with a dihydroorotate hehydrogenase (dhodh) inhibitor
WO2023147161A2 (en) * 2022-01-31 2023-08-03 New Frontier Bio, Inc. Nicotinate and nicotinamide riboside-based compounds and derivatives thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US529490A (en) * 1894-11-20 hegg-em
EP0040896B1 (en) * 1978-08-22 1984-04-25 Sumitomo Chemical Company, Limited Synthesis of amides
JPH05331163A (ja) * 1991-03-26 1993-12-14 Kumiai Chem Ind Co Ltd ピリジン誘導体及び除草剤
PL179417B1 (en) * 1993-10-01 2000-09-29 Novartis Ag Pharmacologically active derivatives of pyridine and methods of obtaining them
TR199701665T1 (xx) 1995-06-21 1998-06-22 Asta Med�Ca Aktingesellschaft B�t�nle�ik �l�me cihaz�na sahip farmas�tik toz kartu�u ve toz halinde t�bbi maddeler i�in soluma cihaz�.
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
WO2000076489A2 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
PT1381356E (pt) 2001-04-05 2008-07-24 Aventis Pharma Inc Utilização de (4' -trifluorometilfenil) - amida do ácido (z) -2- ciano-3-hidroxi-but-2-enóico para tratamento da esclerose múltipla
WO2002102374A1 (en) * 2001-06-19 2002-12-27 Merck & Co., Inc. Amine salt of an integrin receptor antagonist
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
WO2003006424A1 (en) * 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) * 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
SE0400234D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
CA2567602A1 (en) 2004-05-21 2006-01-05 The Uab Research Foundation Compositions and methods relating to pyrimidine synthesis inhibitors
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
CA2584655A1 (en) 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
JP5214971B2 (ja) * 2004-10-20 2013-06-19 メルク セローノ ソシエテ アノニム ３−アリルアミノピペリジン誘導体
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
KR20090110931A (ko) 2007-02-06 2009-10-23 첼시 쎄라퓨틱스, 인코포레이티드 신규한 화합물, 이의 제조방법 및 이의 용도
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2210615A1 (en) 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

Also Published As

Publication number Publication date
CN101589025B (zh) 2012-05-30
PL2121614T3 (pl) 2012-11-30
DK2121614T3 (da) 2012-09-17
TW200833332A (en) 2008-08-16
ES2389785T3 (es) 2012-10-31
HRP20120697T1 (hr) 2012-09-30
HK1133014A1 (en) 2010-03-12
MY153393A (en) 2015-02-13
CA2674512A1 (en) 2008-07-03
US8258308B2 (en) 2012-09-04
PT2121614E (pt) 2012-08-31
AR064444A1 (es) 2009-04-01
AU2007338321B2 (en) 2012-01-19
NZ577017A (en) 2011-12-22
JP5318776B2 (ja) 2013-10-16
ECSP099395A (es) 2009-07-31
RU2469024C2 (ru) 2012-12-10
NO341991B1 (no) 2018-03-12
US8691852B2 (en) 2014-04-08
NO20092380L (no) 2009-07-14
JP2010513362A (ja) 2010-04-30
MX2009006408A (es) 2009-06-23
RU2009127847A (ru) 2011-01-27
ES2319596B1 (es) 2010-02-08
WO2008077639A1 (en) 2008-07-03
UY30794A1 (es) 2008-05-31
TWI405572B (zh) 2013-08-21
IL199188A (en) 2014-06-30
CA2674512C (en) 2015-09-08
CL2007003666A1 (es) 2008-07-04
CN101589025A (zh) 2009-11-25
EP2121614A1 (en) 2009-11-25
PE20081846A1 (es) 2008-12-27
BRPI0717697A2 (pt) 2016-03-22
ME01475B (me) 2014-04-20
US20120294854A1 (en) 2012-11-22
AU2007338321A1 (en) 2008-07-03
CY1113687T1 (el) 2016-06-22
EP2121614B1 (en) 2012-06-20
SI2121614T1 (sl) 2012-10-30
KR20090090352A (ko) 2009-08-25
ES2319596A1 (es) 2009-05-08
RS52514B (en) 2013-04-30
US20100074898A1 (en) 2010-03-25
BRPI0717697B1 (pt) 2022-05-03
KR101435233B1 (ko) 2014-08-28

Similar Documents

Publication Publication Date Title
ZA200903335B (en) Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors
IL242267A0 (en) Solid citrate and tartrate salts of iv– dpp inhibitors
AU2009226958A8 (en) Pyridines and pyrazines as inhibitors of PI3K
SI2178840T1 (sl) Derivativi azabifenilaminobenzojske kisline kot dhodh inhibitorji
IL198171A0 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
IL212670A0 (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
HK1128281A1 (zh) 作為組蛋白去乙酰化酶抑制劑的吡啶和嘧啶衍生物
HK1128284A1 (en) Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
HK1128282A1 (en) Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
EP2170339A4 (en) PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONDEACETYLASE INHIBITORS
HK1133260A1 (en) Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes
IL216132A (en) Heterocyclic carboxamide diamine compounds, their uses and their medicinal products and inhibitors
IL205176A0 (en) Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
ZA200801822B (en) Pyrazine derivatives and use as p13k inhibitors
EP2188295A4 (en) PYRIDINE DERIVATIVES AND METHODS OF USE
IL198487A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
ZA200808364B (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
PT2004155T (pt) Inibidores de agregação proteica
SI2252597T1 (sl) Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze
IL198398A0 (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
ATE530529T1 (de) 5-phenyl-nicotinsäureamid-derivate
EP2083826A4 (en) PYRIMIDINE DERIVATIVES AS POSH AND POSH-AP HEMMER
GB0605295D0 (en) Amino and derivatives
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
ZA200806919B (en) Insecticidal substituted amino heterocyclic and heteraryl derivatives